Clinical Trial: Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Evaluation de la Spironolactone Dans le Traitement Des choriorétinites séreuses Centrales Non résolutives à Trois Mois

Brief Summary:

The objective of the study is to evaluate the effect of spironolactone on 16 patients presenting with chronic non-resolutive central serous chorioretinitis (CSCR) and to evaluate whether spironolactone can resolve sub retinal fluid in these patients.

CSCR is a major cause of visual loss in the young population. It is characterized by sub retinal fluid under the retina and retinal pigment epithelial detachments. The exact causes of the disease remain unknown but a choroidopathy has been suggested. Moreover, corticotherapy and stress are known risk factors of CSCR.

Our preclinical studies have demonstrated that the mineralocorticoid pathway could be involved in the control of choroidal blood flow.

The investigators propose to evaluate the mineralocorticoid receptors antagonist spironolactone in the treatment of CSCR.

Criteria of efficacy Endpoint: reduction of subretinal fluid ≥ 40 microns Secondary endpoint: visual acuity gain ≥ 15 EDTRS letters

Detailed Summary: This is a prospective placebo controlled cross over study including 16 patients
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Current Primary Outcome: Change in Central macular thickness [ Time Frame: 1 and 3 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Institut National de la Santé Et de la Recherche Médicale, France

Dates:
Date Received: February 14, 2012
Date Started: January 2012
Date Completion:
Last Updated: February 24, 2016
Last Verified: February 2016